Cloning and characterization of a human BCR/ABL-positive cell line, K562/RR, resistant to the farnesyltransferase inhibition by tipifarnib

Experimental Hematology

Volumn 35, Issue 9, 2007, Pages 1358-1365

  Miyoshi, Takuji ^a   Nagai, Tadashi ^a   Kikuchi, Satoru ^a   Ohmine, Ken ^a   Nakamura, Makiko ^a   Hanafusa, Toshiaki ^b   Komatsu, Norio ^c   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BETA GLOBIN; CASPASE 3; CASPASE 7; CASPASE 9; CAVEOLIN 2; COMPLEMENTARY DNA; CYCLOOXYGENASE 2; FARNESYLTRANSFERASE ALPHA; FARNESYLTRANSFERASE BETA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEIC ACID BINDING PROTEIN; PROTEIN CUGBP2; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN FEN1; TIPIFARNIB; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CLONING; CELL CYCLE ARREST; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA MICROARRAY; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CLONING, MOLECULAR; DRUG RESISTANCE, NEOPLASM; FARNESYLTRANSTRANSFERASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ABL; HUMANS; K562 CELLS; QUINOLONES;

EID: 34548140545     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.05.020     Document Type: Article

References (28)

1. Rowinsky E.K., Windle J.J., and Von Hoff D.D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 17 (1999) 3631-3652
2. Gibbs R.A. Farnesyltransferase inhibitors: Novel anticancer mechanisms and new therapeutic applications. Curr Opin Drug Dis Dev 3 (2000) 585-596
3. Ashar H.R., James L., Gray K., et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275 (2000) 30451-30457
4. Lebowitz P.F., and Prendergast G.C. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 17 (1998) 1439-1445
5. Gotlib J. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr Hematol Rep 4 (2005) 77-84
6. Le Gouill S., Pellat-Deceunynck C., Harousseau J.L., et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 16 (2002) 1664-1667
7. Feldman E.J. Farnesyltransferase inhibitors in myelodysplastic syndrome. Curr Hematol Rep 4 (2005) 186-190
8. Karp J.E., Lancet J.E., Kaufmann S.H., et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97 (2001) 3361-3369
9. Cortes J., Albitar M., Thomas D., et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101 (2003) 1692-1697
10. Alsina M., Fonseca R., Wilson E.F., et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103 (2004) 3271-3277
11. Del Villar K., Urano J., Guo L., and Tamanoi F. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors. J Biol Chem 274 (1999) 27010-27017
12. Zhang B., Groffen J., and Heisterkamp N. Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a. Blood 106 (2005) 1355-1361
13. Bruzek L.M., Poynter J.N., Kaufmann S.H., and Adjei A.A. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336). Mol Pharmacol 68 (2005) 477-486
14. Smith V., Rowlands M.G., Barrie E., Workman P., and Kelland L.R. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin Cancer Res 8 (2002) 2002-2009
15. Buzzeo R., Enkemann S., Nimmanapalli R., et al. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. Clin Cancer Res 11 (2005) 6057-6064
16. Lassar A.B., Davis R.L., Wright W.E., et al. Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell 66 (1991) 305-315
17. Nagai T., Harigae H., Furuyama K., et al. 5-Aminolevulinate synthase expression and hemoglobin synthesis in a human myelogenous leukemia cell line. J Biochem 121 (1997) 487-495
18. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 (1987) 156-159
19. Miyoshi T., Nagai T., Ohmine K., et al. Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines. Biochem Pharmacol 69 (2005) 1585-1594
20. Mahon F.X., Deininger M.W., Schultheis B., et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96 (2000) 1070-1079
21. Jiang K., Coppola D., Crespo N.C., et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 20 (2000) 139-148
22. Tamanoi F., Gau C.-L., Jiang C., Edamatsu H., and Kato-Stankiewicz J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell Mol Life Sci 58 (2001) 1636-1649
23. Shah N.P., Nicoll J.M., Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
24. Hnasko R., and Lisanti M.P. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv 3 (2003) 445-464
25. Shen B., Singh P., Liu R., et al. Multiple but dissectible functions of FEN-1 nucleases in nucleic acid processing, genome stability and diseases. Bioessays 27 (2005) 717-729
26. Mukhopadhyay D., Houchen C.W., Kennedy S., Dieckgraefe B.K., and Anant S. Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2. Mol Cell 11 (2003) 113-126
27. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 37 (2000) 431-502
28. Kern M.A., Haugg A.M., Koch A.F., et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 66 (2006) 7059-7066